{"entity":{"id":"xencor","kind":"company","name":"Xencor","aka":[],"tldr":"Xencor is an antibody-engineering company (XmAb Fc technology) developing 2+1 T-cell engagers for kidney cancer (ENPP3) and ovarian/germ-cell tumours (CLDN6).","summary":"Xencor, based in Pasadena and listed as XNCR, is an antibody engineering company built on its XmAb Fc technology, developing 2+1 format T-cell engagers for kidney cancer, targeting ENPP3, and for ovarian and germ-cell tumours, targeting Claudin 6. XmAb819, an ENPP3 by CD3 engager, is in clear-cell renal cell carcinoma with a pivotal study planned for 2027, XmAb541, a Claudin 6 by CD3 engager, has produced confirmed partial responses in ovarian and germ-cell tumours, and the XmAb Fc technology is licensed into several approved antibodies. OnCo links it to renal cell carcinoma and ovarian cancer, to T-cell engagers and bispecific antibodies, and to CD3 as a target. Whether T-cell engagers can work in solid tumours without unacceptable toxicity is the question its 2+1 format is designed to answer. The T-cell engager page carries the field.","asOf":"2026-09-04","links":[{"label":"2026 milestones","url":"https://investors.xencor.com/news-releases/news-release-details/xencor-highlights-corporate-priorities-and-2026-pipeline"}],"tags":[],"related":[],"cancers":["rcc","ovarian"],"sections":["immunotherapy","targeted-therapy"],"technologies":["t-cell-engager","bispecific-antibody"],"targets":["cd3"],"drugs":["vudalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Pasadena, CA","country":"US","companyType":"biotech","website":"https://xencor.com","ticker":"XNCR","investors":[],"funding":[]},"route":"/companies/xencor/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"drug":[{"id":"vudalimab","kind":"drug","name":"Vudalimab","route":"/drugs/vudalimab/"}],"trial":[{"id":"nct05032040","kind":"trial","name":"A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies","route":"/trials/nct05032040/"}]}}